Company Overview and News

How Precious Metals and Miners Moving in April?

15h marketrealist
Precious metals had another up day as gold futures for April expiration rose 0.48% on Friday, April 13, closing at $1,344.80 per ounce. Silver rose 1.1%, ending the day at $16.60 per ounce.
Upvote Downvote

US Inflation Rises: How Will It Impact Gold Prices?

2018-04-16 marketrealist
According to the US Bureau of Labor Statistics, the US consumer price index (or CPI) rose 2.4% year-over-year (or YoY) in March 2018. This is its fastest pace in the last 12 months. The core CPI, which excludes volatile food and energy components, rose 0.2% over the previous month and 2.1% YoY in March. This was the biggest gain in core prices since February 2017.
Upvote Downvote

Are US-China Jitters Affecting Precious Metals?

2018-04-10 marketrealist
Gold, silver, platinum, and palladium increased 0.33%, 1%, 2.4%, and 4.2%, respectively, on Monday. Gold futures for April expiration were trading at $1,336.3 an ounce on Monday, April 9. The volatility in gold was at 10.4%, while its RSI level was at 59.7. Silver futures for April expiration closed at $16.5 per ounce. Silver’s volatility was at 17.4% and its RSI level was at 58. Platinum and palladium were at $933.
Upvote Downvote

Alacer Gold Announces Release Date for First Quarter 2018 Operational and Financial Results Conference Call

2018-04-10 globenewswire
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) (ASX:AQG) plans to release its first quarter 2018 operating results, financial statements and the related management’s discussion and analysis before the Toronto Stock Exchange opens on Tuesday, May 1, 2018 (North America).
Upvote Downvote

US Dollar: Its Strong Correlation to Gold in the Past Month

Gold prices fell 0.11% on Thursday, March 29, 2018, and closed at $1,322.80 per ounce. Its call-implied volatility remained at 9.1%, while its RSI (relative strength index) level was 51.5. Gold continues to trade above its 100-day moving average but below its 20-day moving average due to the ongoing slump in gold.
Upvote Downvote

Is an Uptick in Inflation on the Way, Supporting Gold?

The most recent data for the US Consumer Price Index (or CPI) was weaker than expected. The CPI rose 0.2% in February 2018, compared to a 0.5% rise in January 2018.
Upvote Downvote

The Return of Volatility: Good News for Gold Investors

On March 23, 2018, gold futures hit a two-year high. Gold spot prices also rose 3.3% in the week ended March 23—the largest weekly gain since April 2016. The most recent spike in gold prices came after President Trump announced that the US government is considering import tariffs on $60.0 billion in imports from China. China also warned of $3.0 billion in retaliatory tariffs.
Upvote Downvote

Can Gold Keep Shining with Trade War Fears?

On March 22, US president Trump signed a memorandum that could impose tariffs on $60 billion of imports from China. These tariffs could, however, come after a 30-day consultation period that starts once the list is published. The markets were already fearing this move.
Upvote Downvote

US Inflation Softens, Gold Still Has Drivers to the Upside

As per the U.S. Bureau of Labor Statistics, the US Consumer Price Index (or CPI) rose 0.2% in February, compared to a 0.5% rise in January 2018. This inflation figure was in line the market expectation of a 0.2% rise. The year-over-year (or YoY) rise in inflation came in at 1.8% for February 2018, also in line with expectations. The softer inflation figure in February is also in line with the weaker-than-expected growth in wages during the month.
Upvote Downvote

What Drove Gold and Silver Upward?

The two most critical precious metals, gold and silver, rose on March 23, rising 1.4% and 1% in spot markets. Platinum ended the day flat, and palladium was down by 0.4%, as it mostly follows industries.
Upvote Downvote

Analyzing the Volatility in Precious Metals Mining Companies

Precious metals mining companies have been seeing mixed performances over the past few days. Precious metals witnessed a down day on March 15, 2018, which was also mostly elaborated in the performances of mining companies.
Upvote Downvote

Allocation to Cash on the Rise—Could Gold Benefit Too?

According to a survey conducted by Bank of America Merrill Lynch (BAC), fund managers are cautious about further US stock market declines amid rising anxiety. The survey indicates a record jump in the number of investors saying that they are buying protection against a steep decline in equity markets in the next three months.
Upvote Downvote

How Trade War Fears Could Move Precious Metals

All four precious metals saw a down day on Monday, March 5. Gold, silver, platinum, and palladium were down 0.23%, 0.33%, 0.31%, and 0.81%, respectively. The losses in gold prices were eventual, as gold had been trading higher before it tumbled. The fear of trade wars after Donald Trump’s announcement of tariffs on aluminum and steel imports gave gold some buoyancy.
Upvote Downvote

Analyzing Miners’ Performance in February 2018

In this part, we’ll focus on miners’ moving averages and RSI (relative strength index) readings. The miners that we’ll analyze are New Gold (NGD), Sibanye Gold (SBGL), Hecla Mining (HL), and Alacer Gold (ASR).
Upvote Downvote

Alacer's Stock Is Cheap Based On High-Margin ÇöPler Sulphide Project

2018-02-15 seekingalpha
Alacer Gold is positioned to outperform the market as it completes the Çöpler Sulphide Expansion project in 2018.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...